Ampio Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused primarily on the development of therapies to treat prevalent inflammatory conditions. The Company's two lead product candidates in development are Ampion for osteoarthritis of the knee and Optina for diabetic macular edema. The Company is also focused on developing and monetizing its Oxidation Reduction Potential (ORP) diagnostic device and sexual dysfunction portfolio. Ampion is a sub 5000 molecular weight fraction of commercial human serum albumin (HSA) for the treatment of osteoarthritis and other inflammatory conditions. Optina is a low-dose formulation of danazol for the treatment of diabetic macular edema (DME). The Company's subsidiaries include Luoxis Diagnostics, Inc. (Luoxis), an in-vitro diagnostics company, and Vyrix Pharmaceuticals, Inc. (Vyrix), a specialty pharmaceutical company.